Practical use of idarucizumab
The number of patients with indications for direct oral anticoagulants (DOACs) to prevent thrombotic events is steadily growing. However, in 1,1-2,2% of cases, ischemic strokes occur within DOAC therapy. In this case, DOAC use is a limitation for systemic thrombolysis, except for available reversal...
Saved in:
| Main Authors: | G. R. Ramazanov, E. A. Kovaleva, E. V. Klychnikova, S. S. Petrikov, N. A. Shamalov, I. S. Aliev, E. V. Shevchenko |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2023-11-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/3774 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Systemic Thrombolytic Therapy for Ischemic Stroke in the Course of Anticoagulants
by: L. Kh.-B. Akhmatkhanova, et al.
Published: (2021-11-01) -
Idarucizumab more effectively reverses the anticoagulant effects of dabigatran acylglucuronide than dabigatran
by: Jong-Min Kim, et al.
Published: (2025-07-01) -
Dabigatran etexilate in patients with nonvalvular atrial fibrillation: benefits of application in certain clinical situations
by: E. I. Baranova, et al.
Published: (2019-11-01) -
New safety standards for anticoagulant therapy in the treatment of atrial fibrillation
by: E. I. Baranova
Published: (2018-11-01) -
IDARUCIZUMAB, A SPECIFIC REVERSAL AGENT FOR DABIGATRAN: THE PRESENT-DAY KNOWLEDGE
by: Olga O. Shakhmatova
Published: (2018-12-01)